Lunch & Learn San Francisco - June 2017
Date and time
Location
The Westin San Francisco Airport
1 Old Bayshore Highway Millbrae, CA 94030Description
Topic:
Updates in Immunotherapy for Urologic Malignancies
Abstract:
Evading immune recognition is a major hallmark of cancer, and strategies that can overcome this blockade and allow immune cells to recognize and eliminate cancer cells have begun to show impressive clinical results. In urologic cancers immune therapies are approved for prostate, bladder, and renal cancers, including autologous vaccines and inhibitors targeting the PD-1 and PD-L1 immunologic checkpoints, and multiple trials are underway. Major challenges facing the field include identifying why some patients respond to immunotherapy and others don't, establishing the optimal duration of therapy, understanding the phenomenon of pseudoprogression, and evaluating combination therapies. This talk will provide an update on the current clinical use of immunotherapies in urologic malignancies and discuss directions for the future.
Speaker:
Our speaker will be Terry Friedlander, MD, Assistant Clinical Professor, Hematology/Oncology at the University of California, San Francisco. Dr. Friedlander is a clinical and translational oncologist specializing in cancers of the genitourinary tract, specifically bladder and prostate cancers. His research is focused on understanding the basic biology of these malignancies and in developing novel therapeutic ways to treat disease. As a clinical academic oncologist, Dr. Friedlander serves as principle investigator or coinvestigator on a number of clinical trials in advanced prostate and bladder cancer, which allows his team to recruit patients for much of their biomarker work. He hopes that through his work it will help to predict which patients will respond to differing chemotherapies and be able to tailor clinical strategies that will give the most benefit.
This event will be held in the ASPEN room.
Agenda:
12:00-12:30 - Check-in and lunch
12:30-12:45 - Dylan Daniel, PhD, Director, Scientific Development - Welcome & Introduction
12:45-1:15 - Terry Friedlander, MD - Updates in Immunotherapy for Urologic Malignancies
1:15-1:30 - Q&A
1:30-2:00 - Wrap up discussion
Organized by
MI Bioresearch is a leading preclinical oncology and immuno-oncology contract research provider with extensive tumor model experience and advanced in-vivo imaging, flow cytometry, and radiation dosing capabilities. Partner with our scientific team to get the best decision-enabling data to move your drug program forward. One Focus. One Purpose. Oncology Research.